Galapagos
Signal active
Investment Firm
Overview
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.
Highlights
Founded
1999
Industry
Biotechnology
Employees
251-500
Investment
2
Lead Investment
0
Exits
undefined
Stages
Late Stage Venture, Seed
Investor Type
N/A
Location
Europe
Contact Information
Social
Profile Resume
Galapagos, established in 1999 and headquartered in Europe., specializes in Late Stage Venture, Seed investments across Biotechnology, Life Science, Pharmaceutical, Biopharma, Precision Medicine, Venture Capital, Health Care, Oncology, Information Services, Health Insurance. Their recent investments include Frontier Medicines, MPM Capital, Deerfield Management, RA Capital Management, Droia Ventures. The highest investment round they participated in was $10.2B. Among their most notable exits are Frontier Medicines and MPM Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Galapagos has made 2 investments. Their most recent investment was on Feb 22, 2024, when Frontier Medicines raised $80.0M.
investments
2
Diversity investments
0
Lead investments
0
Number of exits
undefined
Investments
2
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jul 01, 2013 | - | - | null |
| Feb 22, 2024 | Frontier Medicines | Biotechnology | 80.0M |
Exits
0
Funding Timeline
Funding rounds
2
Investors
6
Funds
0
Funding Rounds
2
Galapagos has raised 2 rounds. Their latest funding was raised on Feb 22, 2024 from a Series C - Frontier Medicines round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jul 01, 2013 | Seed Round - Vitalnext | - | 0 | - |
| Feb 22, 2024 | Series C - Frontier Medicines | - | 80.0M | - |
Investors
14
Galapagos is funded by 14 investor(s). Gilead Sciences and University of Antwerp Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
| - | No | Grant - Galapagos | 4.0M |
University of Antwerp | No | Grant - Galapagos | 2.8M |
| - | No | Post-IPO Equity - Galapagos | 300.0M |
Gilead Sciences | Yes | Post-IPO Equity - Galapagos | 5100.0M |
University of AntwerpFund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.